The ESMO late-breaking oral presentation slot suggests the data is viewed as noteworthy by the scientific community. The virtual webinar on October 26 will provide the first detailed look at safety and efficacy. Positive data could be a major catalyst; negative or mixed data would be a setback for the pipeline.
Price Chart
Executive Summary
ArriVent announced that initial safety and efficacy data from the Phase 1 study of its CDH17-targeted ADC ARR-217 (MRG007) in gastrointestinal cancers will be presented as a late-breaking oral presentation at the ESMO Congress 2026. The company will host a virtual webinar on October 26, 2026 to discuss the data. This is a key pipeline catalyst for a clinical-stage biotech with no approved products, and the data readout could significantly impact the stock.
Key Facts
- First-in-human Phase 1 data for ARR-217 (CDH17-targeted ADC) selected as a late-breaking oral presentation at ESMO 2026.
- Data will be presented on October 25, 2026 at ESMO Congress in Madrid.
- ArriVent will host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data.
- ARR-217 is the lead ADC candidate from ArriVent's growing ADC portfolio, licensed from Lepu Biopharma for ex-Greater China rights.
- CDH17 is overexpressed in colorectal cancer and other GI cancers, with limited normal tissue expression.
Financial Impact
No financial data disclosed; ARR-217 is a preclinical/Phase 1 asset with no revenue. Positive data could drive significant revaluation for this clinical-stage biotech.
Risk Factors
- Phase 1 data may show insufficient efficacy or unexpected safety signals.
- ARR-217 is still early-stage; clinical failure risk is high.
- The company has no approved products and relies on pipeline success.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387598 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $21.00 (−11.17%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $21.00 (0.00%) |
Oct 23, 2026 3d ago | Press Release | $21.00 | awaiting T+5 | — | $21.00 (0.00%) |
Oct 19, 2026 7d ago | 8-K | $17.94 $15.36 | ▼ −14.38% | ▼ −14.24% | $21.00 (+17.06%) |
Oct 13, 2026 13d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $21.00 (+29.63%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $21.00 (+30.52%) |
Oct 8, 2026 18d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $21.00 (−25.52%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $21.00 (−39.17%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $21.00 (+30.00%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $21.00 (−31.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers